Claims for Patent: 9,138,509

Summary for Patent: 9,138,509

Title:	Composition for filling bone defects
Abstract:	The invention is directed toward an improved formable bone composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone particles ranging from about 100 to 850 microns. The bone particles are mixed in an excipient carrier combination containing carboxymethylcellulose, sodium hyaluronate, and a sodium phosphate saline buffer, the carboxymethylcellulose component of the carrier ranging from about 5.0 to about 11.0% of the composition and the sodium hyaluronate component of the carrier ranging from about 0.3 to about 0.7% of the composition, the composition having a pH between 6.5-7.5.
Inventor(s):	Sunwoo; Moon Hae (Old Tappan, NJ), Lizano; Victor A. (Jersey City, NJ), Gertzman; Arthur A. (Flemington, NJ)
Assignee:	MUSCULOSKELETAL TRANSPLANT FOUNDATION (Edison, NJ)
Application Number:	11/898,722
Patent Claims:	1. A composition for application to a bone defect site, the composition consisting of demineralized or partially demineralized osteoinductive bone particles, a carrier, and optionally, one or more of (i) one or more growth factor additives, (ii) a cellular material taken from the group consisting of living cells and cell elements, (iii) one or more antiviral additives effective against HIV and hepatitis, and (iv) an antimicrobial and/or antibiotic selected from the group consisting of one or more of erythromycin, bacitracin, triclosan, neomycin, penicillin, polymyxin B, tetracycline, viomycin, chloromycetin, streptomycin, cefazolin, ampicillin, azactam, tobramycin, clindamycin, and gentamycin; wherein the bone particles range from about 100 to 850 microns in size, and are present in an amount ranging from about 38% to about 42% (w/w) of the composition; and wherein the carrier consists of carboxymethylcellulose and sodium hyaluronate in one or more of a phosphate buffered aqueous solution, saline, or sterile water, wherein the carboxymethylcellulose and sodium hyaluronate are present in a weight ratio of about 20:1, and wherein the carboxymethylcellulose has a molecular weight in a range of from about 200,000 to about 500,000 Daltons. 2. The composition of claim 1, wherein the bone particles are present in an amount of about 40% (w/w) of the composition. 3. The composition of claim 1, wherein the bone particles are from allograft bone. 4. The composition of claim 3, wherein said allograft bone is selected from cortical bone, corticocancellous bone, cancellous bone, or combinations thereof. 5. The composition of claim 1, wherein the bone particles are from xenograft bone. 6. The composition of claim 4, wherein said xenograft bone is selected from cortical bone, corticocancellous bone, cancellous bone, or combinations thereof. 7. The composition of claim 1, wherein the carboxymethylcellulose is present in an amount ranging from about 5% to about 11% (w/w) of the carrier. 8. The composition of claim 1, wherein the sodium hyaluronate has a molecular weight of at least 700,000 Daltons. 9. The composition of claim 1, wherein the sodium hyaluronate is present in an amount ranging from about 0.1% to about 0.7% (w/w) of the carrier. 10. The composition of claim 1, wherein the sodium hyaluronate is present in an amount of about 0.3% (w/w) of the carrier. 11. The composition of claim 1, wherein said one or more growth factor additives is selected from a transforming growth factor, an insulin growth factor, a platelet derived growth factor, a vascular endothelial growth factor, a fibroblast growth factor, a bone morphogenic protein, osteopontin, cellular attractants and attachment agents, or a growth hormone. 12. The composition of claim 11, wherein said fibroblast growth factor is present in the amount of 2 to 4 milligrams in 10 cc of carrier solution. 13. The composition of claim 1, wherein said cellular material is selected from chondrocytes, red blood cells, white blood cells, platelets, bone marrow cells, mesenchymal stem cells, pluripotential cells, osteoblasts, osteoclasts, fibroblasts, epithelial cells, or endothelial cells. 14. The composition of claim 13, wherein said cellular material is present at a concentration of 10.sup.5 to 10.sup.8 cells per cc of the carrier. 15. The composition of claim 1, wherein the pH of said composition ranges from 6.5 to 7.5. 16. The composition of claim 11, wherein said growth hormone is somatotropin.

Details for Patent 9,138,509

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-22